key: cord-0716021-qs856atq authors: Zuiani, Adam; Wesemann, Duane R. title: Antibody dynamics and durability in COVID-19 date: 2021-11-03 journal: Clin Lab Med DOI: 10.1016/j.cll.2021.10.004 sha: 91d9388de95ae66b2d25d41a1a48aaa121979081 doc_id: 716021 cord_uid: qs856atq COVID-19 has emerged as the greatest global health threat in generations. An unprecedented mobilization of researchers has generated a wealth of data on humoral responses to SARS-CoV-2 within a year of the pandemic’s beginning. The rapidly developed understanding of acute phase antibody induction and medium-term antibody durability in COVID-19 is important at an individual level to inform patient care and a population level to help predict transmission dynamics. In this brief review, we will describe the development and maintenance of antibody responses to immunization and infections generally and the specific antibody dynamics observed for COVID-19. These crucial features of the humoral response have implications for the use of antibody therapeutics against the virus and can inform the likelihood of reinfection of individuals by the virus. COVID-19 has emerged as the greatest global health threat in generations. An unprecedented 34 mobilization of researchers has generated a wealth of data on humoral responses to SARS-35 CoV-2 within a year of the pandemic's beginning. The rapidly developed understanding of acute 36 phase antibody induction and medium-term antibody durability in COVID-19 is important at an 37 individual level to inform patient care and a population level to help predict transmission 38 dynamics. In this brief review, we will describe the development and maintenance of antibody 39 responses to immunization and infections generally and the specific antibody dynamics While there is considerable variation between different infectious diseases and vaccinations, the 45 development of pathogen-specific antibodies follows a similar course in most cases. During a 46 primary exposure the antibody response is generated through the activation of naïve B cells that 47 is uncommon (8, 9, 11, 12, 14, 15) . By two to three weeks after symptom onset, >85% of subjects 126 are reported to seroconvert across studies, with many studies reporting close to 100% 127 seroconversion among symptomatic subjects (8, 9, 11, 13, 14, 16 studies have tracked the difference between antibody levels at peak, approximately one month 226 after symptom onset, and 3 -4 months later (18,20,55-57). As expected, IgM rapidly decays in 227 the months following clearance of SARS-CoV-2, often below limits of detection, with IgA 228 following a similar trend, suggesting weak induction of IgA-producing LLPCs (7,9,52,55,56). The 229 IgG response falls from the initial peak to a lower level but very rarely to baseline (18,20,55-57). 230 Although less data are available for antibody secretion at mucosal sites, one study of antibody 231 levels in saliva suggests that antibodies produced at mucosal surfaces follow a similar pattern to 232 the trends observed in serum (56). Fewer studies are available looking at later timepoints, but 233 the available data are consistent with stable total anti-SARS-CoV-2 antibody levels after the 234 initial decay, including one rigorous study of adaptive immunity up to 8 months following disease 235 onset (50,51). 236 pathogens can be measured using two criteria: the total antibody that binds to viral antigens, 238 most frequently as determined by ELISA, and virus neutralizing antibody, measured by a 239 neutralization assay. A virus neutralizing antibody prevents infection by binding to the capsid or 240 envelope proteins on the surface of the virion that facilitate attachment and entry into host cell. 241 Where an ELISA measures simple binding of an antibody to antigens immobilized on plastic, a 242 neutralization assay measures the capacity of antibodies to block virus from entering live cells. 243 Neutralization is a more stringent measure than binding alone. Only a subset of the total 244 antibody produced against a virus contributes to neutralization; non-neutralizing antibodies can bind to regions of the viral proteins that do not impact its ability to enter cells. Neutralizing 246 antibody titers correlate strongly with vaccine efficacy against other pathogens. If neutralizing 247 antibodies prove to be critical to protection from SARS-CoV-2 reinfection, tracking retention of 248 neutralizing antibody responses will be key to understanding persistence of humoral immunity to 249 SARS-CoV-2. Total anti-SARS-CoV-2 antibodies are retained with some decay for at least 6 250 months post symptoms onset as described above. However, neutralization may show greater 251 susceptibility to decay as neutralizing antibody levels are lower than total antibody level (58). In summary, antibody responses to SARS-CoV-2 follow a typical biphasic response pattern, 292 reaching a peak approximately one month post symptom onset followed by a period of decay to 293 cold-causing HCoVs. However, genetic drift-driven emergence of new viral variants in tandem 297 with frequently weak neutralizing antibody responses conspire to make reinfection risks with 298 heterologous strains a continued concern. An important goal for future work will be to fully 299 understand heterologous strain reinfection frequencies and to identify the degree to which 300 antibody measurements such as neutralizing levels and SARS-CoV-2 variant cross-reactivity 301 inform predictions and gauge risk levels for disease recurrence. Mechanism and control of V(D)J 307 recombination at the immunoglobulin heavy chain locus Mechanism and regulation of class switch 310 Antibody responses to SARS-CoV-2 in patients with COVID-19 Convergent 350 antibody responses to SARS-CoV-2 in convalescent individuals Duration of Humoral Immunity to Common Viral and 396 Vaccine Antigens Safety and 399 immunogenicity of a Zika purified inactivated virus vaccine given via standard, 400 accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, 401 randomised, placebo-controlled, phase 1 trial Seroepidemiology of group I human 416 coronaviruses in children Development of a nucleocapsid-based human coronavirus immunoassay and estimates 419 of individuals exposed to coronavirus in a U.S. metropolitan population Sensitive and Specific Detection of Low-Level Antibody Responses in Mild Middle East 423 Respiratory Syndrome Coronavirus Infections. Emerg Infect Dis J [Internet SARS-coronavirus in SARS patients and their clinical significance Two-year prospective study 443 of the humoral immune response of patients with severe acute respiratory syndrome Disappearance of Antibodies to SARS-Associated Coronavirus after Recovery Robust 466 neutralizing antibodies to SARS-CoV-2 infection persist for months. Science (80-) Prolonged evolution of the human B cell response to SARS-CoV-2 infection An 484 mRNA Vaccine against SARS-CoV-2 -Preliminary Report Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine 488 for Covid-19 A neutralizing human antibody 491 binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science (80-) Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral CoV-2 Variants B.1.351 and B.1.1.7. Nature [Internet Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely 513 unmitigated epidemic. Science (80-) Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence